Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial (Q58000796)

From Wikidata

Jump to navigation Jump to search

article

Language	Label	Description	Also known as
English	Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial	article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22018760%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22018760%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

ChEBI release 2020-05-28

Jose R. Arribas

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22018760%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Jürgen Rockstroh

7

object named as

Jürgen K Rockstroh

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22018760%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

Franco Maggiolo

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22018760%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Aza Rakhmanova

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22018760%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Patrick Yeni

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22018760%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Benjamin Young

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22018760%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Steve Almond

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22018760%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Ivy Song

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22018760%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Cindy Brothers

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22018760%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Sherene Min

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22018760%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Jan van Lunzen

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22018760%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

publication date

20 October 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22018760%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Lancet Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22018760%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22018760%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22018760%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

111-118

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22018760%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Integrase inhibitors to treat HIV/AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970290-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970290-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Raltegravir with optimized background therapy for resistant HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970290-0

7 January 2021

based on heuristic

inferred from DOI database lookup

In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970290-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970290-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970290-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970290-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970290-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of the integrase inhibitor S/GSK1349572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of the VIKING study (ING112961).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970290-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970290-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of trimethoprim on serum creatinine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970290-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970290-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970290-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970290-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1473-3099(11)70290-0

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22018760%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22018760%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q58000796&oldid=1417867564"